Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takashi Seto

Showing results (51-60 of 242) with videos related to

Pageof 25
Sort By:
Internal Medicine (Tokyo, Japan)|May 17, 2006
Pulmonary adenocarcinoma associated with SAPHO syndrome difficult to differentiate from multiple bone metastasisReishi Shibakuki, Takashi Seto, Kazutsugu Uematsu, et al.
Lung Cancer (Amsterdam, Netherlands)|May 16, 2006
Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancerTakashi Seto, Masahiko Higashiyama, Hiroko Funai, et al.
Thoracic Cancer|October 16, 2020
Cohesion between pulmonary artery and bronchus after immune checkpoint inhibitor therapy in a lung cancer patientShinkichi Takamori, Mitsuhiro Takenoyama, Taichi Matsubara, et al.
Thoracic Cancer|June 30, 2022
Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 studyYukio Hosomi, Takashi Seto, Makoto Nishio, et al.
Psycho-Oncology|September 11, 2007
Cancer patients' reluctance to disclose their emotional distress to their physicians: a study of Japanese patients with lung cancerToru Okuyama, Chiharu Endo, Takashi Seto, et al.
Japanese Journal of Clinical Oncology|September 2, 2008
Patient-perceived barriers to the psychological care of Japanese patients with lung cancerChiharu Endo, Tatsuo Akechi, Toru Okuyama, et al.
JTO Clinical and Research Reports|April 20, 2026
Mutation-Specific Response to Ramucirumab in <i>EGFR-</i>Mutated Metastatic NSCLC: Insights From Circulating Cell-Free DNA Profiling (Liquid Biopsy Japan Addendum of RELAY Phase 3 Randomized Study)Kazuto Nishio, Kazuko Sakai, Makoto Nishio, et al.
Palliative & Supportive Care|June 23, 2009
Cancer patients' reluctance to discuss psychological distress with their physicians was not associated with underrecognition of depression by physicians: a preliminary studyToru Okuyama, Chiharu Endo, Takashi Seto, et al.
Translational Lung Cancer Research|September 11, 2023
Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with <i>EGFR</i>-activating mutations (RELAY phase 3 randomized study)Kazuto Nishio, Kazuko Sakai, Makoto Nishio, et al.
Future Oncology (London, England)|January 11, 2020
Therapies after first-line afatinib in patients with <i>EGFR</i>m<sup>+</sup> NSCLC in Japan: retrospective analysis of LUX-Lung 3Hiroshige Yoshioka, Terufumi Kato, Isamu Okamoto, et al.
Pageof 25

Showing results (51-60 of 242) with videos related to

Sort By:
Pageof 25
Internal Medicine (Tokyo, Japan)|May 17, 2006
Pulmonary adenocarcinoma associated with SAPHO syndrome difficult to differentiate from multiple bone metastasisReishi Shibakuki, Takashi Seto, Kazutsugu Uematsu, et al.
Lung Cancer (Amsterdam, Netherlands)|May 16, 2006
Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancerTakashi Seto, Masahiko Higashiyama, Hiroko Funai, et al.
Thoracic Cancer|October 16, 2020
Cohesion between pulmonary artery and bronchus after immune checkpoint inhibitor therapy in a lung cancer patientShinkichi Takamori, Mitsuhiro Takenoyama, Taichi Matsubara, et al.
Thoracic Cancer|June 30, 2022
Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 studyYukio Hosomi, Takashi Seto, Makoto Nishio, et al.
Psycho-Oncology|September 11, 2007
Cancer patients' reluctance to disclose their emotional distress to their physicians: a study of Japanese patients with lung cancerToru Okuyama, Chiharu Endo, Takashi Seto, et al.
Japanese Journal of Clinical Oncology|September 2, 2008
Patient-perceived barriers to the psychological care of Japanese patients with lung cancerChiharu Endo, Tatsuo Akechi, Toru Okuyama, et al.
JTO Clinical and Research Reports|April 20, 2026
Mutation-Specific Response to Ramucirumab in <i>EGFR-</i>Mutated Metastatic NSCLC: Insights From Circulating Cell-Free DNA Profiling (Liquid Biopsy Japan Addendum of RELAY Phase 3 Randomized Study)Kazuto Nishio, Kazuko Sakai, Makoto Nishio, et al.
Palliative & Supportive Care|June 23, 2009
Cancer patients' reluctance to discuss psychological distress with their physicians was not associated with underrecognition of depression by physicians: a preliminary studyToru Okuyama, Chiharu Endo, Takashi Seto, et al.
Translational Lung Cancer Research|September 11, 2023
Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with <i>EGFR</i>-activating mutations (RELAY phase 3 randomized study)Kazuto Nishio, Kazuko Sakai, Makoto Nishio, et al.
Future Oncology (London, England)|January 11, 2020
Therapies after first-line afatinib in patients with <i>EGFR</i>m<sup>+</sup> NSCLC in Japan: retrospective analysis of LUX-Lung 3Hiroshige Yoshioka, Terufumi Kato, Isamu Okamoto, et al.
Pageof 25